Described are devices and methods for use in connection with organ replacement or organ assist therapy in a patient.

Bioartificial ultrafiltration devices comprising a scaffold comprising a population of cells enclosed in a matrix and disposed adjacent a plurality of channels are provided. The population of cells provides molecules such as therapeutic molecules to a subject in need thereof and is supported by the nutrients filtered in an ultrafiltrate from the blood of the subject. The plurality of channels in the scaffold facilitate the transportation of the ultrafiltrate and exchange of molecules between the ultrafiltrate and the population of cells.

An apparatus for the extracorporeal treatment of blood comprising an extracorporeal blood circuit (2), a pump (6) configured to provide fluid displacement within the extracorporeal blood circuit, and a reaction chamber (8) connected to the extracorporeal blood circuit and configured to receive blood or plasma from the circuit and treat the blood or plasma. The reaction chamber comprises a protease enzyme immobilized to a support, in which the protease enzyme is specific for, and capable of irreversibly cleaving, a human C5a present in the blood or plasma, wherein the abundance of the human C5a in the treated blood or plasma is less than that in the untreated blood or plasma. The apparatus finds utility in the extracorporeal treatment of blood from patients with inflammatory conditions, especially auto-immune disease and sepsis.

A system, device, and autologous method for treating blood. Blood is extracted from a patient. The blood is tested to determine one or more pathogens and conditions of the blood. One or more catalysts are automatically added into the blood of the patient. The one or more catalysts are activated utilizing the one or more emitters configured to interact with the one or more catalysts in the blood create treated blood. One or more additives are added into the threated blood. The treated blood is reinjected into the patient.

The present invention relates to a device for the treatment of blood comprising a solid phase on which a polypeptide is immobilized which is suitable for the inactivation of free nucleic acids. Suitable polypeptides are, for example, deoxyribonucleases, ribonucleases, DNA methyltransferases or cytosine deaminases. The invention further comprises the use of such devices for the treatment of patients suffering from chronic kidney failure, cancer or lupus erythematosus, as well as methods and systems for the treatment of blood, wherein free nucleic acids are inactivated outside the body.

The invention relates to a treatment device (100) which is designed for extracorporeal blood treatment of blood of a subject (2) for an immunotolerance enhancement of the subject (2), comprising at least one container (10) which has an interior (11) for receiving a blood sample (1) of blood of the subject (2) and an exchange device (20) designed to supply and/or discharge the blood sample (1) into or out of the interior (11) of the container (10) and comprising a cell exposure device (30) which is positioned in the container (10) and has biological cell material (31) with surface molecules, said cell material being arranged in the interior (11) of the container (10) for a material interaction with the blood sample (1), including a reaction of endogenous immune cells in the blood with the surface molecules of the cell material. The invention also relates to a kit for extracorporeal blood treatment and to a method for operating the treatment device.

A bioartificial liver (BAL) based on human induced pluripotent stem cells (iPSCs)-derived hepatocyte-like cells (HLCs) and a multilayer porous bioreactor is provided. The plasma separation/retransfusion loop part includes a blood input pipe, an exhaust pipe spring clamp, a blood input peristaltic pump, a heparin pump, a plasma separation column, a first pressure monitor, and a heater. The cell reactor/plasma component exchange double-loop part includes a plasma input peristaltic pump, and a semipermeable membrane exchange column, a plasma exchange peristaltic pump, a red blood cell (RBC) pool, a membrane lung, a multilayer porous bioreactor, a second pressure monitor, and a third pressure monitor arranged in a 37° C. dedicated incubator. An outlet of the third pressure monitor and a blood cell outlet are connected to an inlet of the first pressure monitor, and then connected to the heater and a blood output pipe in sequence.

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA); applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC); removing the ARFVC from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed.

Bioartificial ultrafiltration devices comprising a scaffold comprising a population of cells enclosed in a matrix and disposed adjacent a plurality of channels are provided. The population of cells provides molecules such as therapeutic molecules to a subject in need thereof and is supported by the nutrients filtered in an ultrafiltrate from the blood of the subject. The plurality of channels in the scaffold facilitate the transportation of the ultrafiltrate and exchange of molecules between the ultrafiltrate and the population of cells.

Embodiments are described for treating a fluid, e.g., a biological fluid. The embodiments may include systems, apparatuses, and methods. Embodiments may provide for a flow cell, with a plurality of manipulation elements, through which a fluid is flowed. The fluid may be treated (e.g., exposed to energy) as it moves through the flow cell. In embodiments, the flow cell may be used to inactivate pathogens in the fluid.